> ## Content Index
> Fetch the complete content index at: https://www.nrdlplus.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# NHSA Moves Forward with China’s First Dual-List Adjustment for NRDL and Commercial Drug Catalog
- URL: https://www.nrdlplus.com/nhsa-moves-forward-with-chinas-first-dual-list-adjustment-for-nrdl-and-commercial-drug-catalog/
- Published: 2025-07-03T11:00:33.000Z
- Updated: 2026-02-22T02:40:53.000Z
- Description: What will China’s new dual-list mechanism mean for launch timing, pricing risks, and long-term market potential for innovative drugs?
- Author: Kelly Ke
- Tags: Commercial Health Insurance & C-List Dynamics, Pricing & Procurement Governance

[![](https://storage.ghost.io/c/15/10/1510052f-01d9-45db-bfd3-6cc3e958312c/content/images/2025/11/Access360-Subscription-1-1.png)](https://www.nrdlplus.com/archive)

On July 1, China’s National Healthcare Security Administration (NHSA) and the National Health Commission jointly issued *Measures to Support High-Quality Development of Innovative Drugs*, outlining 16 policy actions across five focus areas—from R&D to hospital access and multi-payer coverage.

On the same day, the NHSA also released a draft workplan for the **2025 NRDL and National Commercial Innovative Drug List Adjustment**, opening it for public comment.

Together, these developments underscore strong political resolve to build a full-chain support system for China’s strategic biopharma sector. Among them, the move to establish **a multi-level coverage framework**—**linking basic and commercial insurance**—marks the most substantive step yet to address the long-standing affordability challenge that has hindered access within this broader initiative.

**But what does this mean for global pharma?**

- **In the near term:** Can the new commercial drug list offer earlier launch opportunities with less pricing risk and fewer operational hurdles—or will it distract from system-level, high-volume access?
- **In the mid term:** How will China’s shifting payer priorities and evolving payment architecture reshape pricing and go-to-market strategies?
- **In the long term:** What will this mean for the market potential of China’s innovative medicines sector? And how might it reshape the trade-off decisions companies make when evaluating the China opportunity?

We’ll explore these questions and more at our upcoming **live C-List Strategy Panel.**

🗓 **Thursday, July 18**  
🕙 **10:00 AM US EDT**

Hope you can join us.

---